Literature DB >> 32642287

NNK-mediated upregulation of DEPDC1 stimulates the progression of oral squamous cell carcinoma by inhibiting CYP27B1 expression.

Junfeng Guo1, Shuzuo Zhou1, Ping Huang2, Shuai Xu1, Gang Zhang1, Haitao He3, Yi Zeng4, Cheng-Xiong Xu2, Haesung Kim5, Yinghui Tan1.   

Abstract

Oral squamous cell carcinoma (OSCC) is a prevalent and malignant cancer. However, the molecular mechanism of OSCC progression is not fully understood. In this study, we observed that the DEP domain containing 1 (DEPDC1) protein was overexpressed in OSCC tissues and that the increased expression of DEPDC1 was closely associated with tumor size and poor clinical outcomes in OSCC patients. The results of functional investigations demonstrated that DEPDC1 stimulates OSCC cell proliferation by inhibiting cytochrome P450 family 27 subfamily B member (CYP27B1) expression. Furthermore, we observed that upregulated DEPDC1 expression was closely associated with smoking status in OSCC patients. The results of in vitro experiments showed that the tobacco compound 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) stimulates DEPDC1 expression by promoting the methylation of its gene body by increasing DNMT1 expression in OSCC cells. Notably, the silencing of DEPDC1 dramatically inhibited OSCC growth by inhibiting cell proliferation and inducing apoptosis in vivo. These findings suggest that smoking causes DEPDC1 overexpression in OSCC through DNMT1-regulated DNA methylation and that upregulated DEPDC1 stimulates OSCC cell proliferation by inhibiting CYP27B1 expression. Our results establish a new mechanism of OSCC progression and highlight DEPDC1 as a candidate prognostic biomarker and therapeutic target in OSCC. AJCR
Copyright © 2020.

Entities:  

Keywords:  CYP27B1; DEPDC1; NNK; OSCC

Year:  2020        PMID: 32642287      PMCID: PMC7339267     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  1 in total

1.  FOXO3a‑modulated DEPDC1 promotes malignant progression of nephroblastoma via the Wnt/β‑catenin signaling pathway.

Authors:  Geng Geng; Qinghao Li; Xingqing Guo; Qingbin Ni; Yongtao Xu; Zhaolong Ma; Yongjin Wang; Ming Ming
Journal:  Mol Med Rep       Date:  2022-07-07       Impact factor: 3.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.